317 related articles for article (PubMed ID: 32975679)
21. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS.
Borisov AN; Kutz A; Christ ER; Heim MH; Ebrahimi F
J Clin Endocrinol Metab; 2023 Oct; 108(11):2940-2949. PubMed ID: 37149821
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and Prognostic Value of Non-Alcoholic Fatty Liver Disease in Patients Hospitalized With Decompensated Chronic Heart Failure.
Misan IA; Arisheva OS; Garmash IV; Cabello FR; Kobalava ZD
Kardiologiia; 2023 Dec; 63(12):72-76. PubMed ID: 38156493
[TBL] [Abstract][Full Text] [Related]
23. Steatosis regression assessed by cap after Vitamin 'D' supplementation in NAFLD patients with Vitamin 'D' deficiency.
Emam RF; Soliman AF; Darweesh SK; AbdElmagid RA; Ibrahim OM; Mohamed DM
Eur J Gastroenterol Hepatol; 2024 Jan; 36(1):101-106. PubMed ID: 37942743
[TBL] [Abstract][Full Text] [Related]
24. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
[TBL] [Abstract][Full Text] [Related]
25. Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease.
Ting YW; Wong SW; Anuar Zaini A; Mohamed R; Jalaludin MY
Front Pediatr; 2019; 7():491. PubMed ID: 31850288
[No Abstract] [Full Text] [Related]
26. The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A.
Neshatbini Tehrani A; Hatami B; Helli B; Yari Z; Daftari G; Salehpour A; Hedayati M; Khalili E; Hosseini SA; Hekmatdoost A
Sci Rep; 2024 Mar; 14(1):5134. PubMed ID: 38429385
[TBL] [Abstract][Full Text] [Related]
27. Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease-A Single Blinded Crossover Trial.
Feehan J; Mack A; Tuck C; Tchongue J; Holt DQ; Sievert W; Moore GT; de Courten B; Hodge A
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068729
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.
Ong Lopez AMC; Pajimna JAT
Sci Rep; 2024 Jan; 14(1):2122. PubMed ID: 38267513
[TBL] [Abstract][Full Text] [Related]
29. Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus.
Koullias E; Papavdi M; Athanasopoulos S; Mitrakou A; Deutsch M; Zoumpoulis P; Manesis E; Thanopoulou A; Koskinas J
Cureus; 2024 Feb; 16(2):e53813. PubMed ID: 38465109
[TBL] [Abstract][Full Text] [Related]
30. Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.
Liao Y; Liu L; Yang J; Zhou X; Teng X; Li Y; Wan Y; Yang J; Shi Z
Sci Rep; 2023 Sep; 13(1):14812. PubMed ID: 37684380
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol.
Nasr P; Iredahl F; Dahlström N; Rådholm K; Henriksson P; Cedersund G; Dahlqvist Leinhard O; Ebbers T; Alfredsson J; Carlhäll CJ; Lundberg P; Kechagias S; Ekstedt M
BMC Gastroenterol; 2021 Apr; 21(1):180. PubMed ID: 33879084
[TBL] [Abstract][Full Text] [Related]
32. Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes.
Abdelgani S; Khattab A; Adams J; Baskoy G; Brown M; Clarke G; Larvenenko O; DeFronzo RA; Abdul-Ghani M
Diabetes Care; 2024 Apr; 47(4):668-675. PubMed ID: 38295394
[TBL] [Abstract][Full Text] [Related]
33. [TEN-HOUR INTERMITTENT FASTING PLUS MEDITERRANEAN DIET VERSUS MEDITERRANEAN DIET ALONE FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)].
Milgrom Y; Massarwa M; Hazou W; Shafrir A; Mishraki E; Sanduka S; Safadi R; Benson A
Harefuah; 2024 Feb; 163(2):93-96. PubMed ID: 38431857
[TBL] [Abstract][Full Text] [Related]
34. A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.
Alarfaj SJ; Bahaa MM; Yassin HA; El-Khateeb E; Kotkata FA; El-Gammal MA; Elberri AI; Habba E; Zien El-Deen EE; Khrieba MO; El-Masry TA; Negm WA; Elberri EI
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7607-7619. PubMed ID: 37667938
[TBL] [Abstract][Full Text] [Related]
35. [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
Rasskazova MA; Vorobyev SV; Butova HN
Ter Arkh; 2023 May; 95(4):316-321. PubMed ID: 38158979
[TBL] [Abstract][Full Text] [Related]
36. Effects of polyphenol supplementation on hepatic steatosis, intima-media thickness and non-invasive vascular elastography in obese adolescents: a pilot study protocol.
Moretti JB; Drouin A; Truong C; Youn E; Cloutier A; Alvarez F; Paganelli M; Grzywacz K; Jantchou P; Dubois J; Levy E; El Jalbout R
BMJ Open; 2024 Jan; 14(1):e074882. PubMed ID: 38296273
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey.
Forst T; Botz I; Berse M; Voswinkel S; Strempler ME; Baumann S; Marinez M
J Diabetes Metab Disord; 2024 Jun; 23(1):999-1006. PubMed ID: 38932817
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.
Wong C; Dash A; Fredrickson J; Lewin-Koh N; Chen S; Yoshida K; Liu Y; Gutierrez J; Kunder R
Hepatology; 2023 Sep; 78(3):847-862. PubMed ID: 35993161
[TBL] [Abstract][Full Text] [Related]
39. A scientifically validated combination of garcinol, curcuminoids, and piperine for mild to moderate nonalcoholic steatohepatitis patients-results from a randomized, double-blind, placebo-controlled study.
Majeed M; Nagabhushanam K; Noureddin M; Paulose S; Barik C; Saklecha S; Mundkur L
Front Nutr; 2023; 10():1201186. PubMed ID: 38170037
[TBL] [Abstract][Full Text] [Related]
40. Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial.
Silva-Sperb AS; Moraes HA; Barcelos STA; de Moura BC; Longo L; Michalczuk MT; Cerski CTS; Uribe-Cruz C; da Silveira TR; Álvares-da-Silva MR; Dall'Alba V
Front Nutr; 2024; 11():1362694. PubMed ID: 38600992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
